FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2152594920> ?p ?o ?g. }

• W2152594920 endingPage "424" @default.
• W2152594920 startingPage "418" @default.
• W2152594920 abstract "<i>Background:</i> Aldosterone antagonists have proven efficacy for management of resistant hypertension and proteinuria reduction; however, they are not widely used due to risk of hyperkalemia. This study assesses the risk factors for hyperkalemia in patients with chronic kidney disease (CKD) and resistant hypertension whose blood pressure (BP) is reduced to a guideline goal. <i>Methods:</i> This is a two-center study conducted in university-based hypertension clinics directed by clinical hypertension specialists. Forty-six patients with resistant hypertension and stages 2 or 3 CKD (mean estimated glomerular filtration rate (eGFR) 56.5 ± 16.2 ml/min/1.73 m²) were evaluated for safety and efficacy of aldosterone blockade added to preexisting BP-lowering regimens. All patients were on three mechanistically complementary antihypertensive agents including a diuretic and a renin-angiotensin system blocker. Patients were evaluated after a median of 45 treatment days. The primary endpoint was change in systolic BP. Secondary endpoints included change in serum potassium, creatinine, eGFR, diastolic BP and tolerability. <i>Results:</i> The mean age of the patients studied was 64.9 ± 10.7 years, all were obese and 86% had type 2 diabetes, with 82% being African-American. Addition of aldosterone antagonism yielded a further mean reduction in systolic BP of 14.7 ± 5.1 mm Hg (p = 0.001). Females with BMI >30 and those with a baseline systolic BP >160 mm Hg were more likely to have a greater BP reduction to aldosterone antagonism. In total, 39% of the patients had a >30% decrease in eGFR when the BP goal was achieved. The mean increase in serum potassium was 0.4 mEq/l above baseline (p = 0.001), with 17.3% manifesting hyperkalemia, i.e. serum potassium >5.5 mEq/l. Predictors of hyperkalemia included a baseline eGFR of ≤45 ml/min/1.73 m² in whom serum potassium was >4.5 mEq/l on appropriately dosed diuretics. Contributing risks in this subgroup included a systolic BP reduction of >15 mm Hg associated with an eGFR fall of >30%. <i>Conclusion:</i> Aldosterone antagonism is effective and safe for achieving a BP goal among people with diabetic nephropathy when added to a triple antihypertensive regimen that includes a blocker of the renin-angiotensin system and an appropriately selected and dosed diuretic. Caution is advised when using aldosterone blockade for BP control in people with advanced stage 3 nephropathy with a serum potassium of >4.5 mEq/l for safety reasons." @default.
• W2152594920 created "2016-06-24" @default.
• W2152594920 creator A5012514694 @default.
• W2152594920 creator A5032021350 @default.
• W2152594920 creator A5057799098 @default.
• W2152594920 date "2009-01-01" @default.
• W2152594920 modified "2023-10-10" @default.
• W2152594920 title "Predictors of Hyperkalemia Risk following Hypertension Control with Aldosterone Blockade" @default.
• W2152594920 cites W1481523571 @default.
• W2152594920 cites W1967567897 @default.
• W2152594920 cites W1991106789 @default.
• W2152594920 cites W1993822942 @default.
• W2152594920 cites W1994199177 @default.
• W2152594920 cites W1999186659 @default.
• W2152594920 cites W2000812251 @default.
• W2152594920 cites W2024815453 @default.
• W2152594920 cites W2025002298 @default.
• W2152594920 cites W2061018844 @default.
• W2152594920 cites W2072031119 @default.
• W2152594920 cites W2074391878 @default.
• W2152594920 cites W2087145249 @default.
• W2152594920 cites W2094727696 @default.
• W2152594920 cites W2095199802 @default.
• W2152594920 cites W2100409734 @default.
• W2152594920 cites W2115013092 @default.
• W2152594920 cites W2129950671 @default.
• W2152594920 cites W2132715232 @default.
• W2152594920 cites W2143379919 @default.
• W2152594920 cites W2147273166 @default.
• W2152594920 cites W2156121263 @default.
• W2152594920 cites W2170113769 @default.
• W2152594920 cites W2172086404 @default.
• W2152594920 cites W2297164013 @default.
• W2152594920 cites W2323458614 @default.
• W2152594920 cites W2423241742 @default.
• W2152594920 cites W2463766359 @default.
• W2152594920 cites W2509151133 @default.
• W2152594920 doi "https://doi.org/10.1159/000237742" @default.
• W2152594920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19738369" @default.
• W2152594920 hasPublicationYear "2009" @default.
• W2152594920 type Work @default.
• W2152594920 sameAs 2152594920 @default.
• W2152594920 citedByCount "143" @default.
• W2152594920 countsByYear W21525949202012 @default.
• W2152594920 countsByYear W21525949202013 @default.
• W2152594920 countsByYear W21525949202014 @default.
• W2152594920 countsByYear W21525949202015 @default.
• W2152594920 countsByYear W21525949202016 @default.
• W2152594920 countsByYear W21525949202017 @default.
• W2152594920 countsByYear W21525949202018 @default.
• W2152594920 countsByYear W21525949202019 @default.
• W2152594920 countsByYear W21525949202020 @default.
• W2152594920 countsByYear W21525949202021 @default.
• W2152594920 countsByYear W21525949202022 @default.
• W2152594920 countsByYear W21525949202023 @default.
• W2152594920 crossrefType "journal-article" @default.
• W2152594920 hasAuthorship W2152594920A5012514694 @default.
• W2152594920 hasAuthorship W2152594920A5032021350 @default.
• W2152594920 hasAuthorship W2152594920A5057799098 @default.
• W2152594920 hasConcept C126322002 @default.
• W2152594920 hasConcept C126894567 @default.
• W2152594920 hasConcept C134018914 @default.
• W2152594920 hasConcept C159641895 @default.
• W2152594920 hasConcept C164705383 @default.
• W2152594920 hasConcept C197934379 @default.
• W2152594920 hasConcept C203092338 @default.
• W2152594920 hasConcept C2778375690 @default.
• W2152594920 hasConcept C2778525890 @default.
• W2152594920 hasConcept C2778653478 @default.
• W2152594920 hasConcept C2780243291 @default.
• W2152594920 hasConcept C535046627 @default.
• W2152594920 hasConcept C71924100 @default.
• W2152594920 hasConcept C84393581 @default.
• W2152594920 hasConceptScore W2152594920C126322002 @default.
• W2152594920 hasConceptScore W2152594920C126894567 @default.
• W2152594920 hasConceptScore W2152594920C134018914 @default.
• W2152594920 hasConceptScore W2152594920C159641895 @default.
• W2152594920 hasConceptScore W2152594920C164705383 @default.
• W2152594920 hasConceptScore W2152594920C197934379 @default.
• W2152594920 hasConceptScore W2152594920C203092338 @default.
• W2152594920 hasConceptScore W2152594920C2778375690 @default.
• W2152594920 hasConceptScore W2152594920C2778525890 @default.
• W2152594920 hasConceptScore W2152594920C2778653478 @default.
• W2152594920 hasConceptScore W2152594920C2780243291 @default.
• W2152594920 hasConceptScore W2152594920C535046627 @default.
• W2152594920 hasConceptScore W2152594920C71924100 @default.
• W2152594920 hasConceptScore W2152594920C84393581 @default.
• W2152594920 hasIssue "5" @default.
• W2152594920 hasLocation W21525949201 @default.
• W2152594920 hasLocation W21525949202 @default.
• W2152594920 hasOpenAccess W2152594920 @default.
• W2152594920 hasPrimaryLocation W21525949201 @default.
• W2152594920 hasRelatedWork W1577251610 @default.
• W2152594920 hasRelatedWork W1990676725 @default.
• W2152594920 hasRelatedWork W2006586291 @default.
• W2152594920 hasRelatedWork W2992991141 @default.
• W2152594920 hasRelatedWork W3212622766 @default.
• W2152594920 hasRelatedWork W3213936688 @default.

• next